Through
1/1
Pivoting to study SARS-CoV-2, many scientists on campus have launched new research projects that address the challenges of the pandemic but also prepare us to confront future challenges.
An experimental immunotherapy can temporarily reprogram patients’ immune cells to attack heart fibroblast cells via only a single injection of mRNA.
How decades of mRNA research at Penn made powerful new COVID-19 vaccines possible—and opened a new vista for future discoveries.
Weissman and Karikó’s mRNA technology is recognized for enabling rapid development of highly effective COVID-19 vaccines
With an NSF grant, Penn Engineering researchers are developing a new manufacturing technique that would be able to produce mRNA sequences in a way that removes the need for cryogenic temperatures.
Research from Penn Medicine shows mRNA COVID-19 vaccines are effective at inducing T-cell responses in multiple sclerosis patients who receive B cell-depleting Infusions even if their antibody responses are diminished.
Weissman and Karikó are honored for engineering modified RNA technology which enabled rapid development of effective COVID-19 vaccines.
For their landmark research that set a foundation for the mRNA SARS-CoV-2 vaccines, Drew Weissman and Katalin Karikó have been selected to receive the prize after decades of work.
Pfizer/BioNTech’s vaccine to prevent COVID-19 uses fundamental modified mRNA technology created by Drew Weissman and Katalin Karikó at the Perelman School of Medicine.
The results underline the importance of a second dose and include implications for booster shots.
Researchers led by Scott Hensley of the Perelman School of Medicine have collaborated with Drew Weissman to develop an mRNA vaccine to treat the H5N1 avian flu.
FULL STORY →
Researchers at Penn Medicine have created a human bird flu vaccine using mRNA, the same platform as the COVID-19 vaccine.
FULL STORY →
Researchers led by Scott Hensley of the Perelman School of Medicine are developing an mRNA vaccine for the H5N1 avian flu with support from Nobel Prize cowinner Drew Weissman.
FULL STORY →
Drew Weissman of the Perelman School of Medicine comments on the efficacy of a potential pancreatic cancer vaccine.
FULL STORY →
Drew Weissman of the Perelman School of Medicine is supportive of findings about a pancreatic cancer vaccine, though he says larger studies are needed to determine effectiveness.
FULL STORY →